Sinonasal mucosal melanoma: immunotherapy boosts survival in metastatic disease

  • Ganti A & al.
  • Laryngoscope
  • 25 avr. 2019

  • Par Brian Richardson, PhD
  • Résumés d'articles
L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte. L'accès à l'intégralité du contenu de ce site est reservé uniquement aux professionnels de santé disposant d'un compte.

Takeaway

  • In patients with sinonasal mucosal melanoma (SNMM), immunotherapy is associated with improved OS in cases with metastasis, whereas surgery is associated with improved OS with attainment of negative margins.

Why this matters

  • SNMM has poor prognosis, but its rarity has made identification of optimal treatment modalities challenging; this is the largest study to date.

Key results

  • 1-year OS was 70%, 5-year OS was 24%.
  • Advanced age (HR, 1.02; P=.003), T4 disease (HR, 1.44; P=.010), and distant metastasis (HR, 3.22; P<.001 were associated with reduced os.>
  • Surgical resection was associated with improved OS with achievement of negative margins (HR, 0.44; P<.001>
  • Immunotherapy was associated with improved OS in patients with metastases (HR, 0.14; 95% CI, 0.04-0.49).

Study design

  • 1874 patients with SNMM from the National Cancer Database were analyzed for survival outcomes and associated factors.
  • Funding: Medtronic, Advanced Rx.

Limitations

  • Retrospective study of large database that lacks some specific information.